The Synthesis and Morphology of a Perfluoroalkyl Oligosiloxane@SiO2 Resin and Its Performance in Anti-Fingerprint Coating

In order to improve the hydro- and oleo-phobic properties of anti-fingerprint coating, novel oligosiloxane intermediate bearing perfluorodecyl/octyl and triethoxy silylethylene groups were synthesized; then, a series of nano-hybrid perfluoroalkyl oligosiloxane resins (FSi@SiO2) were synthesized using the hydrolysis and condensation of FVPS with tetraethylorthosilicate. The chemical structure, morphology, and performance of FSi@SiO2 were investigated. The results indicate that the FSi@SiO2 is a nano hybrid fluorinated polysiloxane resin with mean particle sizes of 200–400 nm. And under nanoparticles and perfluoroalkyl groups bonded in the resin, FSi@SiO2 not only showed a micro rough morphology in atomic force microscopy observation but also could provide the treated substrates with excellent hydro- and oleo-phobicity. As a result, the water and oil contact angles reached 120.3° and 87.5° on the treated glass, respectively; meanwhile, fingerprints were easily cleaned without any stains

Problems of education of the caregivers of the person with Alzheimer's disease

The bachelor's thesis reports about problems of Alzheimer's disease. It briefly looks at the history of the illness, introduces diagnostic and therapeutic methods and also mentions alternative options of approach to the patient suffering from this disease. At the last but not least it describes the nursing care about such patient and emphasize the importace of education of the family caregivers. The main part of the thesis is created by quantitative exploratory survey which focuses at three work groups. The first group is represented by family caregivers of the patient with Alzheimer's disease. The survey's main aim is to find out about the amount of the information they have regarding the given problems and the way they deal with their new life situation. The second group is formed by general practicioners and the third group is represented by the home nursing workers. The target of the survey concerning these two groups is to find out about the extent of the education they pursue and eventual obstacles

Disease Burden Due to Herpes Zoster among Population Aged ≥50 Years Old in China: A Community Based Retrospective Survey

<div><p>Objective</p><p>To understand the disease burden due to Herpes Zoster (HZ) among people aged ≥50 years old in China and provide baseline data for future similar studies, and provide evidence for development of herpes zoster vaccination strategy.</p><p>Methods</p><p>Retrospective cohort study was conducted in 4 townships and one community. A questionnaire was used to collect information on incidence and cost of HZ among people aged ≥ 50 years old.</p><p>Results</p><p>The cumulative incidence rate was 22.6/1,000 among people aged ≥ 50 years old. The average annual incidence rate of HZ was 3.43/1,000 among people aged ≥ 50 years old in 2010–2012. Cumulative incidence and average annual incidence rate increased with age: the cumulative incidence of HZ among people aged ≥ 80 years old was 3.34 times of that among 50- years old (52.3/1000vs15.7/1,000); average annual incidence rate rises from 2.66/1,000 among 50- years old to 8.55/1,000 among 80- year old. Cumulative incidence and average annual incidence rate for females were higher than that for males (cumulative incidence, 26.5/1000vs18.7/1,000; annual incidence rate, 3.95/1000vs2.89/1,000). Cumulative incidence and average annual incidence rate in urban were higher than in rural (cumulative incidence, 39.5/1000vs 17.2/1,000; annual incidence rate, 7.65/1000vs2.06/1,000). The hospitalization rate of HZ was 4.53%. And with the increase of age, the rate has an increasing trend. HZ costs 945,709.5 RMB in total, corresponding to 840.6 RMB per patient with a median cost of 385 RMB (interquartile range 171.7–795.6). Factors associated with cost included the first onset year, area, whether hospitalized and whether sequelae left.</p><p>Conclusion</p><p>Incidence rate, complications, hospitalization rate and average cost of HZ increase with age. We recommend that the HZ vaccinations should target people aged ≥50 years old if Zoster vaccine is licensed in China.</p></div

Incidence rate (/1,000) of HZ among people aged ≥ 50 years old from 2010 to 2012.

<p>Incidence rate (/1,000) of HZ among people aged ≥ 50 years old from 2010 to 2012.</p

Cases and cumulative incidence rates of HZ according to first onset age in people aged ≥ 50 years old.

<p>Cases and cumulative incidence rates of HZ according to first onset age in people aged ≥ 50 years old.</p

Hospitalization rates among HZ patients aged ≥ 50 years old and associated factors: logistic regression analysis.

<p>Hospitalization rates among HZ patients aged ≥ 50 years old and associated factors: logistic regression analysis.</p

Cost of HZ among people aged ≥50 years old (RMB).

<p>Cost of HZ among people aged ≥50 years old (RMB).</p

Age specific sequelae occurrence in HZ patients aged ≥ 50 years old.

<p>Age specific sequelae occurrence in HZ patients aged ≥ 50 years old.</p